BlackRock Inc. purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ: OCUL) in the undefined qua

Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Trans

Ocular Therapeutix Inc. (NASDAQ:OCUL) stock is trading higher on Monday as the stock reacts to under

Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD trea

H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers i

Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-mar

BEDFORD, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” o

California State Teachers Retirement System increased its holdings in Ocular Therapeutix, Inc. (NASD

BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” o

Ocular Therapeutix (OCUL) is positioned for a potential 2027 launch of AXPAXLI, with a de-risked reg

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.35 per share versus the Zacks Consens

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.35) per share which beat the analy

Ocular's AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting wi

Ocular Therapeutix NASDAQ: OCUL said it remains on track to submit a New Drug Application for AXPAXL

BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” o

BEDFORD, Mass. , July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular")

Chardan Capital analyst Andreas Argyrides maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy a

BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” o

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy an

Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and raise

Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript

Ocular Therapeutix, Inc. (NASDAQ:OCUL) stock is trading higher on Wednesday as the company prepares

Ocular outlines FDA-aligned AXPAXLI NDA plan for wet AMD by Q4 2026, revises SOL-R study design, and

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safet

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safet

Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead

https://www.sec.gov/ix?doc=/Archives/edgar/data/1393434/000110465926073496/tm2617802d1_8k.htm

BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” o

BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”),

U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also

RBC Capital analyst Lisa Walter reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.40) per share which missed the ana

Ocular Therapeutix shares up on positive data for wet AMD treatment. Company focusing on retinal dis

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy an

Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"))), an integrated biopharmaceutical company

On March 20, 2026, EyePoint, Inc. (the "Company") filed a complaint against Ocular Therapeut

Benzinga's top Wall Street analysts changed outlook on these names: AVAV cut to $290, OCUL raise

Clear Street analyst Bill Maughan maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raise

Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February

Needham analyst Serge Belanger maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and lowers t

Ocular Therapeutix shares tumble after Axpaxli wet AMD trial data disappoints investors, despite mee

(Editor’s note: The future prices of benchmark tracking ETFs, the lede, the economic data, and the h

MDT: -5% | Medtronic Q3 Adj. EPS $1.36 Beats $1.33 Estimate, Sales $9.017B Beat $8.905B Estimate  

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel